Abstracts tagged "lupus nephritis and Urinary Biomarkers"

Abstract Number: 1037 • 2019 ACR/ARP Annual Meeting
Urinary C3d Is a Good Marker for Monitoring Treatment Response After 3 Months of Induction Treatment in Patients with Biopsy Proven Lupus Nephritis
Sujata Ganguly¹, Sanjukta Majumder ², Hafis Muhammed ³, Amita Aggarwal ⁴ and Ramnath Misra ², ¹Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, India, ²Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India, ³SGPGI, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Complement activation is one of the important pathogenic features of lupus nephritis and low serum complements are conventionally used to monitor disease activity in…
Abstract Number: 1575 • 2019 ACR/ARP Annual Meeting
Lymphocyturia Is a Good and Cheap Biomarker for Active Lupus Nephritis and Is Sensitive to Change
Sarit Sekhar Pattanaik¹, Ankita Singh ², Shilpa Venkataraman ³, Ramnath Misra ⁴, Vinita Agrawal ² and Amita Aggarwal ⁵, ¹Sanjay Gandhi post graduate institute of medical sciences, Lucknow, Uttar Pradesh, India, ²Sanjay Gandhi Post Graduate institute of medical science, Lucknow, India, Lucknow, Uttar Pradesh, India, ³Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India, ⁴Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, Lucknow, Uttar Pradesh, India, ⁵Sanjay Gandhi Postgraduate Institute of Medical Sciences, Lucknow, India, Lucknow, Uttar Pradesh, India
Background/Purpose: Multiple urinary biomarkers have been described for lupus nephritis, however none has reached the clinic due to either complex methodology or low discriminatory power.…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].